Activists in several countries are seeking to void patents on the blockbuster hepatitis C drug Sovaldi, saying that the price being sought by its manufacturer, Gilead Sciences, is prohibitive.
The New York-based legal group the Initiative for Medicines, Access and Knowledge (I-MAK) announced on Wednesday that it had filed challenges in Argentina, Brazil, China, Russia and Ukraine. In all those countries except China, the organization is being joined by local patient advocacy groups.
The actions are a sign that the controversy over Sovaldi is spreading beyond the US, where the US$84,000 charge for a course of treatment has strained Medicaid budgets, to middle-income countries.
Sovaldi, when used with another drug, can cure most cases of hepatitis C in 12 weeks with few side effects. That has stoked huge demand for the medicine around the world. Globally about 150 million people have hepatitis C, which gradually destroys the liver.
Gilead is allowing 11 generic drug manufacturers in India to make sofosbuvir, as Sovaldi is known generically, and sell it in 91 developing nations. However, those do not include some middle-income countries like Argentina, Brazil, China and Ukraine, or Russia, which is considered a high-income country by World Bank standards.
I-MAK estimates it would cost US$270 billion to treat the 40 million people with hepatitis C in those five nations, assuming Gilead charges most of the other countries the US$7,500 per treatment it is proposing in Brazil.
“What that means in simple terms is that people who need the drug aren’t getting it or are not going to get it in the near term,” I-MAK founder Priti Radhakrishnan said.
If there were no patents, the generic versions selling for about US$1,000 in India could be sold in those countries as well, she said.
Patent challenges are already under way elsewhere. In January, the Indian patent office denied a patent on sofosbuvir, the active ingredient in Sovaldi, after challenges were filed by I-MAK and others. A patent challenge was filed in February in Europe by humanitarian aid group Doctors of the World.
I-MAK officials said it would be too expensive for them to try to nullify Gilead’s patents in the US. However, they said they have received inquiries from others, whom they would not identify, who might be interested.
Gilead corporate and medical affairs executive vice president Gregg Alton said the company was “working to facilitate broad patient access to its hepatitis C treatments as quickly as possible in as many places as possible.”
He said at least 50,000 people in lower-income countries had already been treated with sofosbuvir.
“We recognize that challenges to our intellectual property are an inevitable consequence of implementing such a worldwide access effort with such breakthrough products,” he said in an e-mailed statement.
Gilead has also faced challenges to its patents on HIV drugs, some from the same groups now trying to block its hepatitis patents.
Alton said Gilead would soon sign an agreement with the government in Brazil that would allow for a significant increase in the number of patients treated.
Brazilian lawyer Marcela Vieira said the Brazilian government was proposing to treat only people whose livers already show signs of damage. If the price were lower than the US$7,500 Gilead is proposing, the government might be able to treat less advanced cases, preventing liver damage, she said.
Vieira — who coordinates a coalition called the Working Group on Intellectual Property for the Brazilian Network for the Integration of Peoples — said that with more than US$16 billion in global hepatitis C sales since Sovaldi reached the market in late 2013, Gilead had “already recouped much, much more than was spent” on research and development for the drug.
Patents have not been granted yet in Argentina, Brazil and Ukraine, so in those places the groups are set to seek to prevent them from being issued.
The challengers say that sofosbuvir is not novel compared with compounds disclosed in other patent applications.
“Despite sofosbuvir’s medical benefits, it’s really based on old science,” Radhakrishnan said.
That might be a hard case to make. Even the deputy patent controller in India, a nation in which it is notoriously difficult to patent drugs, wrote in his decision in January that he had “no hesitation to acknowledge the novelty and inventive step” of sofosbuvir.
Nevertheless, he denied that patent under a controversial clause in India’s patent law that requires a patented drug to be more effective in treating patients than an older, similar one. The clause was the reason the Indian Supreme Court denied a patent to Novartis for its leukemia drug, Gleevec.
In the case of sofosbuvir, Gilead had failed to show that it was more effective than a compound disclosed in a patent filing by another company that Gilead says was never even developed as a drug.
The case has now been sent back to the patent office to be re-examined.
The activists face other hurdles as well. Sofosbuvir can be protected by many patents, though I-MAK says there are two main ones. Also, sofosbuvir cannot be used alone and some of the drugs it can be paired with have patents and high prices of their own.
However, even if the challenges ultimately fail, the activists hope the pressure could move Gilead to make some concessions.
Recently, China launched another diplomatic offensive against Taiwan, improperly linking its “one China principle” with UN General Assembly Resolution 2758 to constrain Taiwan’s diplomatic space. After Taiwan’s presidential election on Jan. 13, China persuaded Nauru to sever diplomatic ties with Taiwan. Nauru cited Resolution 2758 in its declaration of the diplomatic break. Subsequently, during the WHO Executive Board meeting that month, Beijing rallied countries including Venezuela, Zimbabwe, Belarus, Egypt, Nicaragua, Sri Lanka, Laos, Russia, Syria and Pakistan to reiterate the “one China principle” in their statements, and assert that “Resolution 2758 has settled the status of Taiwan” to hinder Taiwan’s
Singaporean Prime Minister Lee Hsien Loong’s (李顯龍) decision to step down after 19 years and hand power to his deputy, Lawrence Wong (黃循財), on May 15 was expected — though, perhaps, not so soon. Most political analysts had been eyeing an end-of-year handover, to ensure more time for Wong to study and shadow the role, ahead of general elections that must be called by November next year. Wong — who is currently both deputy prime minister and minister of finance — would need a combination of fresh ideas, wisdom and experience as he writes the nation’s next chapter. The world that
The past few months have seen tremendous strides in India’s journey to develop a vibrant semiconductor and electronics ecosystem. The nation’s established prowess in information technology (IT) has earned it much-needed revenue and prestige across the globe. Now, through the convergence of engineering talent, supportive government policies, an expanding market and technologically adaptive entrepreneurship, India is striving to become part of global electronics and semiconductor supply chains. Indian Prime Minister Narendra Modi’s Vision of “Make in India” and “Design in India” has been the guiding force behind the government’s incentive schemes that span skilling, design, fabrication, assembly, testing and packaging, and
Can US dialogue and cooperation with the communist dictatorship in Beijing help avert a Taiwan Strait crisis? Or is US President Joe Biden playing into Chinese President Xi Jinping’s (習近平) hands? With America preoccupied with the wars in Europe and the Middle East, Biden is seeking better relations with Xi’s regime. The goal is to responsibly manage US-China competition and prevent unintended conflict, thereby hoping to create greater space for the two countries to work together in areas where their interests align. The existing wars have already stretched US military resources thin, and the last thing Biden wants is yet another war.